PARP1 and glioma: Finally, to investigate whether this effect could also be observed in tumour progression in vivo, we used a preclinical glioma model generated by inoculation of either Parp1+/+ cRb−/− RasV12 or Parp1−/− cRb−/− RasV12 glial cells in mice.